Medscape42m
FDA Approves Fifth Ustekinumab Biosimilar
The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
BioSpace4h
Lilly’s Omvoh Beats J&J’s Stelara in Head-to-Head Phase III Crohn’s Disease Trial
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Managed Healthcare Executive6h
FDA Approves Imuldosa, the Fifth Stelara Biosimilar
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Pharmabiz13h
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
Drug Store News20h
FDA approves Dong-A ST’s Stelara biosimilar
“This FDA approval indicates global ... a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...
FDA Approves IMULDOSA (ustekinumab-srlf), Accord BioPharma's Biosimilar to STELARA (ustekinumab), for the Treatment of Chronic Inflammatory Conditions
FDA approval of IMULDOSA was granted based on a comprehensive clinical development program. The data showed that IMULDOSA is similar to its reference product STELARA in terms of pharmacokinetic ...